Anticonvulsant activity of aqueous extract of *Aquilaria agallocha*

RITESH JAIN¹, K. NANDAKUMAR¹, VISHAL SRIVASTAVA¹, SANTOSH KUMAR VAIDYA¹, SHAILESH PATEL¹, PRADEEP KUMAR² and LALIT KUMAR

¹Department of Pharmacology, P.E.S College of Pharmacy, Bangalore, India
²Department of Pharmaceutical Analysis, P.E.S. Collage of Pharmacy, Bangalore, (India).
³Department of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Karnataka (India)

(Received: February 12, 2008; Accepted: April 04, 2008)

ABSTRACT

Anticonvulsant activity of the aqueous extracts of *Aquilaria agallocha* Roxb. family Thymelaeaceae was studied in Swiss albino mice using the Pentylene tetrazole (PTZ) and Maximal electroshock (MES) convulsion. In Pentylene tetrazole (PTZ) induced convulsion model, aqueous extracts of *Aquilaria agallocha* (AQAA) 300 and 600 mg/kg, p.o doses significantly increased both the onset of clonus and tonic convulsions induced by PTZ. The effect was dose dependent. In Maximal electroshock (MES) induced convulsion model, 300 mg/kg dose of AQAA exhibited significant anticonvulsant effect, there is significant decrease in the duration of extensor phase with increase in the latency of clonus convulsion. The 600 mg/kg of AQAA also increased the latency of clonus in both acute and chronic studies and decreased the duration of extensor phase. From the experimental study it can be concluded that aqueous extract of heartwood of *Aquilaria agallocha* had exhibited significant anticonvulsant activity in mice.

Key words: *Aquilaria agallocha*, Convulsion, Pentylene tetrazole (PTZ), Maximal electroshock (MES), Phenytoin, and Diazepam.

INTRODUCTION

Seizures are discrete, time-limited alterations in brain function including changes in motor activity, autonomic function, consciousness, or sensation, that result from an abnormal and excessive electrical discharge of a group of neurons within the brain. It has been shown to affect several brain activities and promote long-term changes in multiple neural systems¹.

Epilepsy is the most common chronic disorder of the central nervous system (CNS) manifested by recurrent unprovoked seizures that affect approximately 1% of the U.S. population². It is estimated that there are 50 million people with epilepsy world wide and the majority of cases are in developing countries. This disorder, if untreated, can lead to impaired intellectual function or death and is typically accompanied by psychopathological consequences such as loss of self-esteem³.

Agar wood (*Aquilaria agallocha*) is one of such plant that has been used in Ayurvedic formulation for the treatment of mental illness.⁴ Traditionally it is known to strengthen the brain, *Aquilaria agallocha* has to enhance cerebral function, balance the mind or body connection and the nervous system. In Japanese system of medicine it has been used as a sedative and anxiolytic agents. It is reported to possess CNS depressant activity in mice⁵.

The plant was traditionally used as laxative, diuretic, stomachic, used in chronic diarrhoea, disease of the liver and intestines, bronchitis, asthma, vomiting, gout, rheumatism and headache. In China the wood is used as tonic, stimulant,
carminative, aphrodisiac, in the treatment of snakebite and scorpion-sting. (charaka, sushruta)\(^6\).

However there is lack of scientific data regarding its anticonvulsant activity. Hence it was thought worthwhile to study the aqueous extract of *Aquilaria agallocha* for anticonvulsant activity in mice.

**MATERIAL AND METHODS**

**Plant material**

Heart wood of *Aquilaria agallocha* was purchased from Green Pharmacy, Pune and was authenticated by Green Pharmacy, Pune, India Vide letter no.GPP/411/2004.

**Drugs**

1. Diazepam (Ranbaxy laboratories limited, HMTD Textiles, Mumbai, India)
2. Phenytoin (Sun Pharmaceutical India Ltd, Halol, Gujarat, India)
3. Pentylene tetrazole (St.Louis, MO USA) were used for the pharmacological investigation.

Other chemicals used for extraction and phytochemical investigation were of analytical grade from S.D fine chemicals, Mumbai, India.

**Animals**

Swiss albino mice (18-22 g) purchased from Bioneeds, Tumkur were maintained in the animal house of PES College of Pharmacy, Bangalore for experimental purpose. Then all the animals were acclimatized for seven days under standard husbandry conditions, i.e.; room temperature of 25 ± 1°C; relative humidity 45-55% and a 12:12h light/dark cycle. The animals had free access to standard rat pellet (Pranav Agro Industries Ltd, Mysore feeds, India), with water supplied *ad libitum* under strict hygienic conditions. The approval of the Institutional Animal Ethical Committee (IAEC) of P.E.S College of Pharmacy Bangalore (Karnataka) was taken prior to the experiments. All the protocols and the experiments were conducted in strict compliance according to ethical principles and guidelines provided by Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA).

**Preparation of aqueous extract**

The plant material was dried, powdered and it was extracted with petroleum ether, 95% ethanol and water successively. Aqueous extraction was done by maceration process for 72 hours with chloroform water. The solvents were removed by vacuum distillation and extracts were dried below 50°C. The percentage yield of the aqueous extract was 2% w/w.

**Preliminary phytochemical investigations**

The preliminary phytochemical investigations were carried out with aqueous extract of *Aquilaria agallocha* for qualitative identification of phytochemical constituents present with the extract. Tests were carried out by following standard methods.

**Acute oral toxicity studies**

Female Swiss albino mice (18-22 g) were individually identified and allowed to acclimate to the laboratory conditions for 7 days before the start of the study. Only one mouse received a dose at a particular time. First animal received a dose of 55 mg/kg, p.o. Animal was observed for 48 hours after injection, for any toxicity signs, survival or death. If the first animal died or appeared moribund, the second animal received a lower dose (17.5 mg/kg). The dose progression or reduction factor was 3.2 times of the previous dose. If no mortality was observed in the first animal then the second animal received a higher dose (175 mg/kg). Dosing of the next animal was continued depending on the outcome of the previously dosed animal for a fixed time interval (48 hour). The test was stopped when one of the stopping criteria was met:

- 5 reversals occur in any 6 consecutive animals tested.
- 3 consecutive animals died at one dose level.

Survived animals were observed for long-term outcomes for a period of 14 days. The LD\(_{50}\) values were calculated using AOT 425 software (Environmental Protection Agency, USA) based on the short term (48 hour) and long term out come (14 days)\(^7\).

**Determination of anticonvulsant activity**

Pentylenetetrazole induced convulsion (PTZ) induced convulsions\(^8\)

Male albino mice weighing between 20-
25g were divided into five groups each comprising of six animals and were treated as follows:

- **Group I**: Control (3% Tween-80 p.o.)
- **Group II**: Standard drug (diazepam, 5 mg/kg p.o.)
- **Group III**: Low dose of AQAA (300 mg/kg p.o.)
- **Group IV**: Higher dose of AQAA (600 mg/kg p.o.)

**Experimental procedure**

One hour after vehicle/standard/extract treatment PTZ (pentylenetetrazole 80 mg/kg) was administered i.p. to all groups of mice. Each animal was placed in to individual plastic cage and were observed initially for 30 min and later up to 24 hrs. The following parameters were recorded during test session of initial 30 min and up to 24 hrs: Latency (onset of clonus), Onset of tonic convulsions, Status of animal after 30 minutes, Status of animal after 24 hrs, Percent protection.

**Sataical analysis**

The values were expressed as mean ± SEM from 6 animals. The results were subjected to statistical analysis by using ANOVA followed by Tukey-Kramer test to calculate the significance difference if any among the groups. *P*<0.05 was considered as significant.

**RESULTS**

**Preliminary phytochemical screening**

The aqueous extract of *Aquilaria agallocha* (AQAA) subjected for preliminary phytochemical investigation and found to contain flavonoids, tannins, saponins, carbohydrates and triterpenoids.

**Acute Oral Toxicity Study**

Different doses of AQAA were screened for their oral toxicity and it was found that AQAA was safe up to the dose of 5 g/kg.

**Assessment of anticonvulsant activity**

**PTZ (Pentylenetetrazole) induced convulsions**

AQAA was subjected for anticonvulsant effect using PTZ induced convulsions model in mice. The study revealed that lower dose (300 mg/kg) of AQAA had significantly altered onset of clonus and onset of tonic seizures, but higher dose exhibited much significant anticonvulsant effect by increasing latency, onset of tonic seizures and 33.33% of animals were survived with lower dose and 83.33% survived with higher dose at 30 min interval but only 16.66% of animals survived after 24 hrs with lower dose. (Table 1, figure 1 & 2.)

**MES (Maximal Electro Shock) induced convulsions**

AQAA was subjected for its anticonvulsant effect using MES induced convulsion model. In this study, two dose of AQAA (300 and 600 mg/kg) when administered as single doses, lower dose had exhibited a significant anticonvulsant effect by altering the duration of tonic extensor but no significant difference in latency of clonus with 33.33% of protection against convulsions. Higher dose also exhibited significant effect on duration of tonic extensor phase and also exhibited significant effect with latency of clonus with 83.33% of protection from convulsions (Table 2, Figure 3 & 4.)
Each bar represents Values in mean ± SEM from 6 mice. Significant at **P<0.01 and ***P<0.001 as compare to control using one-way ANOVA followed by Turkey's post hoc test.

**Fig. 1: Effect of AQAA (300 and 600 mg/kg) on latency to produce clonus convulsion in PTZ induced convulsion**

**Fig. 2: of AQAA (300 and 600 mg/kg) on latency to produce tonic convulsion in PTZ induced convulsion**
In this study, with PTZ induced convulsion model, parameters like latency, onset of tonic convulsions and percent protection were observed after treatment with AQAA. Diazepam, 5 mg/kg had prevented tonic and clonus convulsions and offered 100% protection. AQAA 300 mg/kg dose has significantly increased the latency of clonus and tonic phase and offered 16.66 percentage protection. But higher 600 mg/kg significantly increased the onset of both clonus and tonic phases and shown 83.33 percentage protection.

Pentylenetetrazole is a selective blocker of the chloride ionophore complex to the GABA-A receptor, and after repeated or single dose administration leads to a decrease in GABAergic function and to the stimulation and modification of density or sensitivity of different glutamate receptor subtypes in many brain regions. Pentylenetetrazole may also trigger a variety of biochemical processes including the activation of membrane phospholipases, proteases, and nucleases. Marked alteration in membrane phospholipid metabolism result in the liberation of free fatty acids (FFAs), diacylglycerols, eicosanoids, lipid peroxides and free radicals.10 These results suggest that AQAA with 300 and 600mg/kg doses has exhibited significant anti convulsant effect by increasing both the onset of clonus and onset of tonic convulsions and greater effect was recorded with higher dose but not with lower dose. Hence these drug may able to modulate the function of GABA (or) glutamate receptor.

In this study of MES-induced convulsion model, lower dose (300mg/kg) as well as higher dose (600mg/kg) of AQAA both has offered anti convulsant effect against electroshocks induced convulsions. In this study, phenytoin 25mg/kg had prevented clonus convulsions with a 100% protection and produced tonic flexion convulsion. AQAA with dose of 300 mg/kg had shown a significant anti convulsant effects by altering the duration of extensor phase but not onset of clonus and offered 33.33%, protection without producing flexion convulsions. But the dose of 600 mg/kg has significantly altered both duration of extensor phase as well as onset of clonus and offered 83.33%, protection without producing flexion convulsions. In this study it was observed that if, the tonic flexion convulsions produced, onset of clonus and percent

**DISCUSSION**

Different doses of AQAA were screened for there oral toxicity and it was found that AQAA was not toxic up to the dose of 5g/kg based on the toxicity studies. Two doses 300 and 600 mg/kg dose were selected to determine anticonvulsant activity of AQAA.
protection will increase with decrease the duration of tonic extensor.

These results suggest that the lower dose (300 mg/kg) of AQAA has less anti convulsant effect than higher dose (600mg/kg) of AQAA; which may be due to the more sedative effect with higher (600mg/kg) dose.

Since AQAA has able to protect PTZ and MES induced convulsions, the drug may possess anti-convulsant activity of generalized in nature. From the experimental study it can be concluded that aqueous extract of heartwood of Aquilaria agallocha had exhibited significant anticonvulsant activity in mice.

Phytoconstituents like flavonoids and saponins were reported for their anxiolytic and anti convulsant effect and these two were present in aqueous extract. These active principles can be accounted for both anxiolytic and anti convulsant effect. However, further studies including toxicological evaluation and the use of more purified fractions are necessary to confirm and extend the present findings.

REFERENCES